Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:43:39.868Z.
Calculation as of: 2026-10-06T20:43:39.868Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc3fa1fa429e6ac4f0d7012b2af5cf8e78abb5153a19c38995711b2f102458f4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
YD Bio Limited Ordinary Shares
Market Cap
$435.61M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$438.07M
EV/EBITDA Ratio
N/A
TTM Avg
81.39x
3Y Avg
32.05x
5Y Avg
24.98x
Market Cap
$439.55M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$442.34M
EV/EBITDA Ratio
N/A
TTM Avg
0.21x
3Y Avg
0.21x
5Y Avg
0.21x
Market Cap
$426.51M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$445.71M
EV/EBITDA Ratio
0.44x
TTM Avg
1.11x
3Y Avg
1.11x
5Y Avg
1.11x
Market Cap
$424.10M
EV/EBITDA Ratio
N/A
TTM Avg
74.72x
3Y Avg
37.71x
5Y Avg
26.88x
Market Cap
$422.86M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| YD Bio Limited Ordinary Shares (YDES) | $435.61M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | N/A | 81.39x | 32.05x | 24.98x |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $442.34M | N/A | 0.21x | 0.21x | 0.21x |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | 0.44x | 1.11x | 1.11x | 1.11x |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | N/A | 74.72x | 37.71x | 26.88x |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | N/A | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | 22.89x | 25.27x | 25.27x | 25.27x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
